These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35580930)

  • 1. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
    Riccardo F; Tarone L; Camerino M; Giacobino D; Iussich S; Barutello G; Arigoni M; Conti L; Bolli E; Quaglino E; Merighi IF; Morello E; Dentini A; Ferrone S; Buracco P; Cavallo F
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.
    Riccardo F; Iussich S; Maniscalco L; Lorda Mayayo S; La Rosa G; Arigoni M; De Maria R; Gattino F; Lanzardo S; Lardone E; Martano M; Morello E; Prestigio S; Fiore A; Quaglino E; Zabarino S; Ferrone S; Buracco P; Cavallo F
    Clin Cancer Res; 2014 Jul; 20(14):3753-62. PubMed ID: 24874834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.
    Piras LA; Riccardo F; Iussich S; Maniscalco L; Gattino F; Martano M; Morello E; Lorda Mayayo S; Rolih V; Garavaglia F; De Maria R; Lardone E; Collivignarelli F; Mignacca D; Giacobino D; Ferrone S; Cavallo F; Buracco P
    Vet Comp Oncol; 2017 Sep; 15(3):996-1013. PubMed ID: 27146852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma.
    Tarone L; Giacobino D; Camerino M; Maniscalco L; Iussich S; Parisi L; Giovannini G; Dentini A; Bolli E; Quaglino E; Merighi IF; Morello E; Buracco P; Riccardo F; Cavallo F
    Mol Ther; 2023 Aug; 31(8):2342-2359. PubMed ID: 37312451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: A retrospective study on 155 cases.
    Giacobino D; Camerino M; Riccardo F; Cavallo F; Tarone L; Martano M; Dentini A; Iussich S; Lardone E; Franci P; Valazza A; Manassero L; Del Magno S; De Maria R; Morello E; Buracco P
    Vet Comp Oncol; 2021 Dec; 19(4):651-660. PubMed ID: 33751759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
    Mayayo SL; Prestigio S; Maniscalco L; Rosa G; Aricò A; Maria R; Cavallo F; Ferrone S; Buracco P; Iussich S
    Vet J; 2011 Nov; 190(2):e26-e30. PubMed ID: 21482159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
    Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
    J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.
    Grosenbaugh DA; Leard AT; Bergman PJ; Klein MK; Meleo K; Susaneck S; Hess PR; Jankowski MK; Jones PD; Leibman NF; Johnson MH; Kurzman ID; Wolchok JD
    Am J Vet Res; 2011 Dec; 72(12):1631-8. PubMed ID: 22126691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
    Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
    Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen.
    Gyorffy S; Rodriguez-Lecompte JC; Woods JP; Foley R; Kruth S; Liaw PC; Gauldie J
    J Vet Intern Med; 2005; 19(1):56-63. PubMed ID: 15715049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
    J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of prognostic impact of pre-treatment neutrophil to lymphocyte and lymphocyte to monocyte ratios in dogs with oral malignant melanoma treated with surgery and adjuvant CSPG4-antigen electrovaccination: an explorative study.
    Camerino M; Giacobino D; Iussich S; Ala U; Riccardo F; Cavallo F; Martano M; Morello E; Buracco P
    Vet Comp Oncol; 2021 Jun; 19(2):353-361. PubMed ID: 33443307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti-CSPG4 vaccination: A retrospective study on 68 cases (2010-2020).
    Camerino M; Giacobino D; Manassero L; Iussich S; Riccardo F; Cavallo F; Tarone L; Olimpo M; Lardone E; Martano M; Del Magno S; Buracco P; Morello E
    Vet Comp Oncol; 2022 Mar; 20(1):189-197. PubMed ID: 34392602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
    Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
    Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunology and canine malignant melanoma: A comparative review.
    Atherton MJ; Morris JS; McDermott MR; Lichty BD
    Vet Immunol Immunopathol; 2016 Jan; 169():15-26. PubMed ID: 26827834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
    Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
    J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
    Kurokawa T; Imai K
    Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.
    Alexander AN; Huelsmeyer MK; Mitzey A; Dubielzig RR; Kurzman ID; Macewen EG; Vail DM
    Cancer Immunol Immunother; 2006 Apr; 55(4):433-42. PubMed ID: 15965647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
    Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
    Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Williams IP; Crescioli S; Sow HS; Bax HJ; Hobbs C; Ilieva KM; French E; Pellizzari G; Cox V; Josephs DH; Spicer JF; Karagiannis SN; Mele S
    MAbs; 2020; 12(1):1685349. PubMed ID: 31769737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.